Analysts Have Conflicting Sentiments on These Healthcare Companies: Immunocore Holdings (IMCR), Warby Parker (WRBY) and Ocular Therapeutix (OCUL)

TipRanksMay 10 01:41 ET

Ocular Therapeutix Is Maintained at Buy by HC Wainwright & Co.

Ocular Therapeutix Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMay 8 15:29 ET

Ocular Therapeutix Price Target Cut to $14.00/Share From $16.00 by HC Wainwright & Co.

Ocular Therapeutix Price Target Cut to $14.00/Share From $16.00 by HC Wainwright & Co.

Dow JonesMay 8 15:29 ET

HC Wainwright & Co. Maintains Buy on Ocular Therapeutix, Lowers Price Target to $14

HC Wainwright & Co. analyst Yi Chen maintains Ocular Therapeutix with a Buy and lowers the price target from $16 to $14.

Analyst UpgradesMay 8 15:19 ET

Ocular Therapeutix Is Maintained at Market Outperform by JMP Securities

Ocular Therapeutix Is Maintained at Market Outperform by JMP Securities

Dow JonesMay 8 14:18 ET

Ocular Therapeutix Price Target Cut to $22.00/Share From $24.00 by JMP Securities

Ocular Therapeutix Price Target Cut to $22.00/Share From $24.00 by JMP Securities

Dow JonesMay 8 14:18 ET